Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FGF-2 gene-carrying Sendai virus vector
- Development stage
- Unknown
- Lead developer
- DNAVEC
- Modality
- Gene Therapies
- Administration
- Intramuscular
01
Overview
FGF-2 gene-carrying Sendai virus vector (also known as DVC1-0101 or ΔFSeV/FGF-2) is an investigational gene therapy developed by ID Pharma (a subsidiary of I'rom Holdings) for the treatment of peripheral arterial disease (PAD), including intermittent claudication and critical limb ischemia (CLI). It utilizes an F (fusion) gene-deleted, non-transmissible recombinant Sendai virus (rSeV) vector to deliver the human fibroblast growth factor-2 (FGF-2) transgene directly into target muscle tissue via intramuscular injection. Upon expression, the human FGF-2 protein promotes therapeutic angiogenesis and vascular regeneration by inducing endogenous angiogenic factors such as VEGF and HGF. The candidate has been evaluated in Phase I/IIa and Phase IIb clinical trials in Japan.
- Other names
- recombinant F-gene-deleted non-transmissible Sendai virus vector expressing human fibroblast growth factor-2recombinant Sendai virus vector carrying human fibroblast growth factor-2 gene
02
Targets
FGF2FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)HGF (Hepatocyte growth factor)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))VEGFA (Vascular endothelial growth factor A)FGFR (FGFR family)
Beyond the preview
Go deeper on FGF-2 gene-carrying Sendai virus vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FGF-2 gene-carrying Sendai virus vector.